Warfarin: A case history in pharmacogenetics

Heart

Volumn 91, Issue 5, 2005, Pages 563-564

  Hall, A M ^a   Wilkins, Martin R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; CYTOCHROME P450 2C9; HYDROQUINONE; MENADIONE EPOXIDE; PROTHROMBIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SMALL INTERFERING RNA; VITAMIN K GROUP; WARFARIN;

ANIMAL MODEL; ANTICOAGULANT THERAPY; BLEEDING; DIETARY INTAKE; DRUG MECHANISM; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MISSENSE MUTATION; NONHUMAN; PATIENT MONITORING; PHARMACOGENETICS; PRESCRIPTION; PRIORITY JOURNAL; PROTHROMBIN TIME; RAT; REVIEW; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOEMBOLISM;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; DRUG DESIGN; DRUG RESISTANCE; HUMANS; PHARMACOGENETICS; WARFARIN;

EID: 17644374218     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2004.051771     Document Type: Review

References (20)

1. Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 2003;41:1633-52.
2. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993;95:315-28.
3. Douketis JD, Foster GA, Crowther MA, et al. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 2000;160:3431-6.
4. Scordo MG, Pengo V, Spina E, et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002;72:702-10.
5. Gage BF, Eby CS. Pharmacogenetics and anticoagulant therapy. J Thromb Thrombolysis 2003;16:73-8.
6. Rettie AE, Wienkers LC, Gonzalez FJ, et al. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994;4:39-42.
7. Haining RL, Hunter AP, Veronese ME, et al. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 1996;333:447-58.
8. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-9.
9. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000;96:1816-19.
10. Gage BF, Eby C, Milligan PE, et al. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004;91:87-94.
11. Hillman MA, Wilke RA, Caldwell MD, et al. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 2004;14:539-47.
12. Margaglione M, Colaizzo D, D'Andrea G, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000;84:775-8.
13. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287:1690-8.
14. Kohn MH, Pelz HJ. A gene-anchored map position of the rat warfarin-resistance locus, Rw, and its orthologs in mice and humans. Blood 2000;96:1996-8.
15. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004;427:537-41.
16. Li T, Chang CY, Jin DY, et al. Identification of the gene for vitamin K epoxide reductase. Nature 2004;427:541-4.
17. Cardon LR, Idury RM, Harris TJ, et al. Testing drug response in the presence of genetic information: sampling issues for clinical trials. Pharmacogenetics 2000;10:503-10.
18. Scordo MG, Caputi AP, D'Arrigo C, et al. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004;50:195-200.
19. Wadelius M, Sorlin K, Wallerman O, et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J 2004;4:40-8.
20. D'Andrea G, D'ambrosio RL, Di Perna P, et al. A polymorphism in VKORC1 gene is associated with an inter-individual variability in the dose-anticoagulant effect of warfarin. Blood 2004;epub (9 September).